06 3377 5059

Transcript

06 3377 5059
IL CURRICULUM
VITAE
INFORMAZIONI PERSONALI
Nome
Indirizzo
Telefono
Fax
E-mail
Nazionalità
Data di nascita
TUBARO ANDREA
VIA VAL PELLICE, 53 – 00141 ROMA
06 3377 5469 / 7712 (ufficio) – 335 8185925 (cellulare)
06 3377 5059
[email protected]
Italiana
3 dicembre 1958
ESPERIENZA LAVORATIVA
• Date (1 novembre 2010 - oggi)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e responsabilità
Dirigente di I° livello
Azienda Ospedaliera Sant’Andrea, Via di Grottarossa 1035 – 00189 Roma
• Date (1 novembre 2001 – 31
ottobre 2010)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Principali mansioni e responsabilità
Dirigente di II° livello
• Date (1 novembre 2001 – oggi)
• Nome e indirizzo del datore di
lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Date (1 novembre 2000 – 31 ottobre
2001)
• Nome e indirizzo del datore di lavoro
• Tipo di azienda o settore
• Tipo di impiego
• Date (1 novembre 1988 – 31 ottobre
2000)
• Nome e indirizzo del datore di lavoro
• Tipo di azienda o settore
• Tipo di impiego
Pagina 1 - Curriculum vitae di
[ TUBARO Andrea ]
Medicina
Tempo pieno
RESPONSABILE U.O.C. DI UROLOGIA
Azienda Ospedaliera Sant’Andrea, Via di Grottarossa 1035 – 00189 Roma
Medicina
Tempo pieno
RESPONSABILE U.O.S. DI CHIRURGIA MININVASIVA
Professore Associato di Urologia
2a Facoltà di Medicina e Chirurgia ora Facoltà di Medicina e Psicologia, Sapienza Università di
Roma
Università
Tempo pieno
Ricercatore confermato
Facoltà di Medicina e Chirurgia, Università di L’Aquila
Università
Tempo pieno
Tecnico Laureato (VIII° livello)
Facoltà di Medicina e Chirurgia, Università di L’Aquila
Università
Tempo pieno
ISTRUZIONE E FORMAZIONE
• Date (1994)
• Nome e tipo di istituto di istruzione
o formazione
• Principali materie / abilità
professionali oggetto dello studio
• Qualifica conseguita
Membro Board Europeo di Urologia
European Board of Urology (EBU)
• Date (1983 – 1988)
• Nome e tipo di istituto di istruzione
o formazione
• Principali materie / abilità
professionali oggetto dello studio
• Qualifica conseguita
Specializzazione in Urologia
Sapienza Università di Roma
• Date (1984)
• Nome e tipo di istituto di istruzione
o formazione
• Principali materie / abilità
professionali oggetto dello studio
• Qualifica conseguita
Esame di Stato
Ordine dei Medici di Roma
• Date (1983 -1988)
• Nome e tipo di istituto di istruzione
o formazione
• Principali materie / abilità
professionali oggetto dello studio
• Qualifica conseguita
Corso di Laurea in Medicina e Chirurgia
Sapienza Università di Roma
Pagina 2 - Curriculum vitae di
[ TUBARO Andrea ]
Urologia
Riconoscimento della specializzazione da parte del Board Europeo di Urologia
Urologia
Specialista in Urologia
Medicina
Abilitazione all’esercizio della professione medica
Medicina
Medico Chirurgo
MADRELINGUA
ITALIANO
ALTRE LINGUA
INGLESE
• Capacità di lettura
• Capacità di scrittura
• Capacità di espressione orale
CAPACITÀ E COMPETENZE
RELAZIONALI
CAPACITÀ E COMPETENZE
ORGANIZZATIVE
.
CAPACITÀ E COMPETENZE
ECCELLENTE
ECCELLENTE
ECCELLENTE
COORDINAMENTO GRUPPI DI STUDIO E DI RICERCA SCIENTIFICA:
- COMITATO IMAGING DELLA CONSULTAZIONE INTERNAZIONALE SULLA CONTINENZA, ANNI 2002, 2005,
2008, 2012
- Gruppi di ricerca diversi, come testimoniato dalla produzione scientifica allegata ed in
particolare nei seguenti campi: immunoterapia locale dei tumori uroteliali, termoterapia
transuretrale a microonde, diagnostica elettromagnetica dei tumori urologici.
- DIREZIONE DI UNITÀ OPERATIVA COMPLESSA
- PARTECIPAZIONE AL CONSIGLIO DI AMMINISTRAZIONE DI SOCIETÀ SCIENTIFICHE: SOCIETÀ EUROPEA
DI UROLOGIA, SOCIETÀ ITALIANA DI UROLOGIA, SOCIETÀ ITALIANA DI URODINAMICA.
- PARTECIPAZIONE AL COMITATO ESECUTIVO DI SOCIETÀ SCIENTIFICHE: SOCIETÀ ITALIANA DI
UROLOGIA
- FONDAZIONE DEL UFFICIO PER LA RICERCA CLINICA DELLA SOCIETÀ EUROPEA DI UROLOGIA
UTILIZZO PACCHETTI INFORMATICI WINDOWS, MAC OS X, OFFICE, SPSS
TECNICHE
ALTRE CAPACITÀ E COMPETENZE
PATENTE O PATENTI
Pagina 3 - Curriculum vitae di
[ TUBARO Andrea ]
ATTIVITÀ DI RICERCA COME TESTIMONIATO DALLA ALLEGATA PRODUZIONE SCIENTIFICA COMPRENDENTE:
- 149 PUBBLICAZIONE RECENSITE SU MEDLINE
- 5 libri a stampa
- 15 capitoli di libri
Patente di guida B
ARTICOLI SCIENTIFICI SU RIVISTE
RECENSITE IN MEDLINE
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Pagina 4 - Curriculum vitae di
[ TUBARO Andrea ]
Tubaro A, Puccini F, De Nunzio C, et al. The treatment of lower urinary
tract symptoms in patients with multiple sclerosis: a systematic review.
Curr Urol Rep. Oct 2012;13(5):335-342.
Tubaro A. Assessment of lower urinary tract symptoms in men by
international prostate symptom score and core lower urinary tract
symptom score. BJU international. May 2012;109(10):1517.
Tubaro A. Acute Urinary Retention Increases the Risk of Complications
after Transurethral Resection of the Prostate: A Population-Based Study.
BJU international. Oct 4 2012.
Tubaro A. Chronic Urinary Retention in Men: Can We Define It, and Does
It Affect Treatment Outcome. BJU international. Mar 27 2012.
Pelin M, Sosa S, Della Loggia R, et al. The cytotoxic effect of palytoxin on
Caco-2 cells hinders their use for in vitro absorption studies. Food Chem
Toxicol. Feb 2012;50(2):206-211.
Novara G, Tubaro A, Sanseverino R, et al. Systematic review and metaanalysis of randomized controlled trials evaluating silodosin in the
treatment of non-neurogenic male lower urinary tract symptoms
suggestive of benign prostatic enlargement. World J Urol. Sep 28 2012.
Lucas MG, Bosch RJ, Burkhard FC, et al. EAU Guidelines on Surgical
Treatment of Urinary Incontinence. European urology. Sep 17 2012.
Lucas MG, Bosch RJ, Burkhard FC, et al. EAU Guidelines on Assessment
and Nonsurgical Management of Urinary Incontinence. European urology.
Aug 31 2012.
Leonardo C, Franco G, De Nunzio C, et al. Salvage laparoscopic radical
prostatectomy following high-intensity focused ultrasound for treatment
of prostate cancer. Urology. Jul 2012;80(1):130-133.
Leonardo C, De Nunzio C, Michetti P, et al. Plication corporoplasty versus
Nesbit operation for the correction of congenital penile curvature. A longterm follow-up. International urology and nephrology. Feb 2012;44(1):5560.
De Sio M, Yakoubi R, De Nunzio C, et al. Reporting quality of abstracts
presented at the European association of urology meeting: a critical
assessment. The Journal of urology. Nov 2012;188(5):1883-1886.
De Nunzio C, Tubaro A. BPH: unmet needs in managing LUTS--a European
perspective. Nat Rev Urol. Jan 2012;9(1):9-10.
De Nunzio C, Leonardo C, Franco G, et al. When to perform bone scan in
patients with newly diagnosed prostate cancer: external validation of a
novel risk stratification tool. World J Urol. May 11 2012.
Cotterill N, Goldman H, Kelleher C, Kopp Z, Tubaro A, Brubaker L. What
are the best outcome measures when assessing treatments for LUTD?-achieving the most out of outcome evaluation: ICI-RS 2011. Neurourology
and urodynamics. Mar 2012;31(3):400-403.
Cornu JN, Abrams P, Chapple CR, et al. A Contemporary Assessment of
Nocturia: Definition, Epidemiology, Pathophysiology, and Management-a
Systematic Review and Meta-analysis. European urology. Nov
2012;62(5):877-890.
Cicione A, Cantiello F, De Nunzio C, Tubaro A, Damiano R. Prostate biopsy
quality is independent of needle size: a randomized single-center
prospective study. Urologia internationalis. 2012;89(1):57-60.
Bove P, Lacovelli V, De Nunzio C, et al. Critical review of laparoendoscopic
single-site surgery versus multiport laparoscopy in urology. Arch Esp
Urol. Apr 2012;65(3):348-356.
Banez LL, Albisinni S, Freedland SJ, Tubaro A, De Nunzio C. The impact of
obesity on the predictive accuracy of PSA in men undergoing prostate
biopsy. World J Urol. Jul 31 2012.
Apostolidis A, de Nunzio C, Tubaro A. What determines whether a patient
with LUTS seeks treatment? ICI-RS 2011. Neurourology and urodynamics.
Mar 2012;31(3):365-369.
Albisinni S, De Nunzio C, Tubaro A, Barry WT, Banez LL, Freedland SJ.
Greater percent-free testosterone is associated with high-grade prostate
cancer in men undergoing prostate biopsy. Urology. Jul 2012;80(1):162167.
Albisinni S, De Nunzio C, Tubaro A. Pure small cell carcinoma of the
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
Pagina 5 - Curriculum vitae di
[ TUBARO Andrea ]
prostate: A rare tumor. Indian J Urol. Jan 2012;28(1):89-91.
Tubaro A, Koelbl H, Laterza R, Khullar V, de Nunzio C. Ultrasound imaging
of the pelvic floor: where are we going? Neurourology and urodynamics.
Jun 2011;30(5):729-734.
Tubaro A, De Nunzio C. Words of wisdom. Re: Safety and feasibility of the
prostatic urethral lift: a novel, minimally invasive treatment for lower
urinary tract symptoms (LUTS) secondary to benign prostatic
hyperplasia (BPH). European urology. Nov 2011;60(5):1120-1121.
Tubaro A, De Nunzio C. Editorial comment. Urology. Oct 2011;78(4):935936; author reply 936.
Tubaro A. Assessment of Lower Urinary Tract Symptoms in Men by
International Prostate Symptom Score and Core Lower Urinary Tract
Symptom Score. BJU international. Aug 26 2011.
Thuroff JW, Abrams P, Andersson KE, et al. [EAU Guidelines on Urinary
Incontinence]. Actas Urol Esp. Jul-Aug 2011;35(7):373-388.
Thuroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary
incontinence. European urology. Mar 2011;59(3):387-400.
Staskin D, Tubaro A, Norton PA, Ashton-Miller JA. Mechanisms of
continence and surgical cure in female and male SUI: surgical research
initiatives. Neurourology and urodynamics. Jun 2011;30(5):704-707.
Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined
therapy with dutasteride plus tamsulosin or either monotherapy in men
with benign prostatic hyperplasia (BPH) by baseline characteristics: 4year results from the randomized, double-blind Combination of Avodart
and Tamsulosin (CombAT) trial. BJU international. Mar 2011;107(6):946954.
Madersbacher S, Alcaraz A, Emberton M, et al. The influence of family
history on prostate cancer risk: implications for clinical management. BJU
international. Mar 2011;107(5):716-721.
Leonardo C, De Nunzio C, Michetti P, et al. Plication corporoplasty versus
Nesbit operation for the correction of congenital penile curvature. A longterm follow-up. International urology and nephrology. May 11 2011.
Laterza RM, De Gennaro M, Tubaro A, Koelbl H. Female pelvic congenital
malformations. Part I: embryology, anatomy and surgical treatment. Eur J
Obstet Gynecol. 2011.
Laterza RM, De Gennaro M, Tubaro A, Koelbl H. Female pelvic congenital
malformations. Part II: sexuality, reproductive outcomes and
psychological impact. Eur J Obstet Gynecol. 2011.
De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship
between benign prostatic hyperplasia and prostate cancer: the role of
inflammation. European urology. Jul 2011;60(1):106-117.
De Nunzio C, Freedland SJ, Miano R, et al. Metabolic syndrome is
associated with high grade gleason score when prostate cancer is
diagnosed on biopsy. Prostate. Feb 25 2011.
De Nunzio C, Freedland SJ, Miano L, Finazzi Agro E, Banez L, Tubaro A.
The uncertain relationship between obesity and prostate cancer: An
Italian biopsy cohort analysis. Eur J Surg Oncol. Dec 2011;37(12):10251029.
De Nunzio C, Cicione A, Leonardo F, et al. Extraperitoneal radical
cystectomy and ureterocutaneostomy in octogenarians. International
urology and nephrology. Sep 2011;43(3):663-667.
De Nunzio C, Carluccini A, Cicione A, et al. Prostate Cancer Does Not
Influence Androgen Levels: A Radical Prostatectomy Cohort Study. Urol
Int. Jan 21 2011.
De Nunzio C, Carbone A, Albisinni S, et al. Long-term experience with
early single Mitomycin C instillations in patients with low-risk nonmuscle-invasive bladder cancer: prospective, single-centre randomised
trial. World J Urol. Aug 2011;29(4):517-521.
De Nunzio C, Albisinni S, Freedland SJ, et al. Abdominal obesity as risk
factor for prostate cancer diagnosis and high grade disease: A prospective
multicenter Italian cohort study. Urol Oncol. Sep 16 2011.
Cindolo L, De Nunzio C, Sountoulides P, Bantis A, Tubaro A, Schips L. The
influence of ejaculation and abstinence on urinary flow rates.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
Pagina 6 - Curriculum vitae di
[ TUBARO Andrea ]
Neurourology and urodynamics. Nov 2011;30(8):1571-1575.
Chu DI, De Nunzio C, Gerber L, et al. Predictive value of digital rectal
examination for prostate cancer detection is modified by obesity. Prostate
Cancer Prostatic Dis. Dec 2011;14(4):346-353.
Brookman-May S, May M, Zigeuner R, et al. Collecting System Invasion
and Fuhrman Grade But Not Tumor Size Facilitate Prognostic
Stratification of Patients With pT2 Renal Cell Carcinoma. The Journal of
urology. Dec 2011;186(6):2175-2181.
Athanasopoulos A, Chapple C, Fowler C, et al. The role of antimuscarinics
in the management of men with symptoms of overactive bladder
associated with concomitant bladder outlet obstruction: an update.
European urology. Jul 2011;60(1):94-105.
Tubaro A, Mariani S, De Nunzio C, Miano R. Bladder weight and detrusor
thickness as parameters of progression of benign prostatic hyperplasia.
Curr Opin Urol. Jan 2010;20(1):37-42.
Tubaro A, De Nunzio C, Mariani S, et al. Reduction of prostate-specific
antigen after tamsulosin treatment in patients with elevated prostatespecific antigen and lower urinary tract symptoms associated with low
incidence of prostate cancer at biopsy. Urology. Aug 2010;76(2):436-441.
Thuroff JW, Abrams P, Andersson KE, et al. EAU Guidelines on Urinary
Incontinence. Eur Urol. Nov 24 2010.
Miano R, Scoffone C, De Nunzio C, et al. Position: Prone or Supine Is the
Issue of Percutaneous Nephrolithotomy. J Endourol. Mar 26 2010.
Madersbacher S, Alcaraz A, Emberton M, et al. The influence of family
history on prostate cancer risk: implications for clinical management. BJU
Int. Dec 16 2010.
Kirby MG, Wagg A, Cardozo L, et al. Overactive Bladder: Is There a Link to
the Metabolic Syndrome in Men? Neurourol Urodyn. Jun 29 2010.
Franco G, De Nunzio C, Leonardo C, et al. Ultrasound assessment of
intravesical prostatic protrusion and detrusor wall thickness--new
standards for noninvasive bladder outlet obstruction diagnosis? J Urol.
Jun 2010;183(6):2270-2274.
De Nunzio C, Miano R, Trucchi A, et al. Photoselective prostatic
vaporization for bladder outlet obstruction: 12-month evaluation of
storage and voiding symptoms. J Urol. Mar 2010;183(3):1098-1103.
De Gennaro M, Niero M, Capitanucci ML, et al. Validity of the international
consultation on incontinence questionnaire-pediatric lower urinary tract
symptoms: a screening questionnaire for children. J Urol. Oct 2010;184(4
Suppl):1662-1667.
de Boer TA, Salvatore S, Cardozo L, et al. Pelvic organ prolapse and
overactive bladder. Neurourol Urodyn. 2010;29(1):30-39.
D'Eliseo D, Pisu P, Romano C, et al. Granzyme B is expressed in urothelial
carcinoma and promotes cancer cell invasion. Int J Cancer. Sep 1
2010;127(6):1283-1294.
Bright E, Oelke M, Tubaro A, Abrams P. Ultrasound Estimated Bladder
Weight and Measurement of Bladder Wall Thickness-Useful Noninvasive
Methods for Assessing the Lower Urinary Tract? J Urol. Sep 15 2010.
Abrams P, Andersson KE, Birder L, et al. Fourth International
Consultation on Incontinence Recommendations of the International
Scientific Committee: Evaluation and treatment of urinary incontinence,
pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn.
2010;29(1):213-240.
Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP. The impact of
lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int.
Apr 2009;103 Suppl 3:33-41.
Suardi N, Gallina A, Salonia A, et al. Open prostatectomy and the evolution
of HoLEP in the management of benign prostatic hyperplasia. Minerva
Urol Nefrol. Sep 2009;61(3):301-308.
Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and
postmicturition symptoms and implications for treatment seeking in the
USA, UK and Sweden: EpiLUTS. BJU Int. Apr 2009;103 Suppl 3:12-23.
McVary K, Tubaro A, De Nunzio C. The Motion: PDE5 Inhibitors are a
Promising Therapy for Benign Prostatic Hyperplasia. Eur Urol. Jul 31
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
Pagina 7 - Curriculum vitae di
[ TUBARO Andrea ]
2009.
De Nunzio C, Trucchi A, Miano R, et al. The number of cores positive for
high grade prostatic intraepithelial neoplasia on initial biopsy is
associated with prostate cancer on second biopsy. J Urol. Mar
2009;181(3):1069-1074; discussion 1074-1065.
D'Eliseo D, Pisu P, Romano C, et al. Granzyme B is expressed in urothelial
carcinoma and promotes cancer cell invasion. Int J Cancer. Dec 21 2009.
Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract
symptoms: evaluating the effect of LUTS on health-related quality of life,
anxiety and depression: EpiLUTS. BJU Int. Apr 2009;103 Suppl 3:4-11.
Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary
tract symptoms (LUTS) in the USA, the UK and Sweden: results from the
Epidemiology of LUTS (EpiLUTS) study. BJU Int. Mar 5 2009.
Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R. Is there
evidence of a relationship between benign prostatic hyperplasia and
prostate cancer? Findings of a literature review. Eur Urol. Apr
2009;55(4):864-873.
Tubaro A, De Nunzio C, Trucchi A, Stoppacciaro A, Miano L. The
Electromagnetic Detection of Prostatic Cancer: Evaluation of Diagnostic
Accuracy. Urology. Mar 10 2008;72:5.
Miano R, De Nunzio C, Asimakopoulos AD, Germani S, Tubaro A.
Treatment options for benign prostatic hyperplasia in older men. Med Sci
Monit. Jul 2008;14(7):RA94-102.
Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality
of life: pooled data from two randomized trials. BJU Int. Jul
2008;102(1):56-61.
Iori F, Franco G, Leonardo C, et al. Bipolar transurethral resection of
prostate: clinical and urodynamic evaluation. Urology. Feb
2008;71(2):252-255.
De Nunzio C, Miano R, Trucchi A, Finazzi Agro E, Tubaro A. Finasteride for
prostatic disease: an updated and comprehensive review. Expert Opin
Drug Metab Toxicol. Dec 2008;4(12):1561-1568.
van Adelsberg J, Gann P, Ko AT, et al. The VIOXX in Prostate Cancer
Prevention study: cardiovascular events observed in the rofecoxib 25 mg
and placebo treatment groups. Curr Med Res Opin. Sep 2007;23(9):20632070.
Tubaro A, De Nunzio C, Miano R. Transurethral needle ablation of the
prostate. Curr Opin Urol. Jan 2007;17(1):7-11.
Tubaro A. Testosterone and prostate cancer. Eur Urol. Feb
2007;51(2):293-295.
Scarpa RM, Carrieri G, Gussoni G, et al. Clinically overt venous
thromboembolism after urologic cancer surgery: results from the
@RISTOS Study. Eur Urol. Jan 2007;51(1):130-135; discussion 136.
Keane T, Gillatt D, Evans CP, Tubaro A. Current and Future Trends in the
Treatment of Renal Cancer. European Urology Supplements. 2007;6(3):11.
Gravina GL, Costa AM, Galatioto GP, Ronchi P, Tubaro A, Vicentini C.
Urodynamic obstruction in women with stress urinary incontinence--do
nonintubated uroflowmetry and symptoms aid diagnosis? J Urol. Sep
2007;178(3 Pt 1):959-963; discussion 963-954.
Gacci M, Del Popolo G, Artibani W, et al. Visual assessment of
uroflowmetry curves: description and interpretation by urodynamists.
World J Urol. Jun 2007;25(3):333-337.
Evans CP, Debruyne FMJ, Payne H, Solsona E, Teillac P, Tubaro A. Bladder
Cancer: Management and Future Directions. European Urology
Supplements. 2007;6(3):9.
Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and
tolerability of once-daily fesoterodine in subjects with overactive bladder.
Eur Urol. Oct 2007;52(4):1204-1212.
Tubaro A, Zattoni F, Prezioso D, et al. Italian validation of the
International Consultation on Incontinence Questionnaires. BJU Int. Jan
2006;97(1):101-108.
Tubaro A, Batista JE, Berges R, et al. Future Directions in Evaluating
Nocturia and Its Impact in Patients with LUTS/BPH. European Urology
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
Pagina 8 - Curriculum vitae di
[ TUBARO Andrea ]
Supplements. 2006;5(1):3.
Tubaro A. Micronutrients and BPH. Eur Urol. Sep 2006;50(3):413-415.
Tubaro A. BPH treatment: a paradigm shift. Eur Urol. Jun 2006;49(6):939941.
Saad F, Higano CS, Sartor O, et al. The role of bisphosphonates in the
treatment of prostate cancer: recommendations from an expert panel.
Clin Genitourin Cancer. Mar 2006;4(4):257-262.
Roehrborn CG, Lotan Y, Tubaro A, de Nunzio C. Open to debate. The
motion: prevention of prostate cancer with a 5alpha-reductase inhibitor
is feasible. Eur Urol. Feb 2006;49(2):396-400.
Naspro R, Suardi N, Salonia A, et al. Holmium laser enucleation of the
prostate versus open prostatectomy for prostates >70 g: 24-month
follow-up. European urology. Sep 2006;50(3):563-568.
De Gennaro M, Capitanucci ML, Di Ciommo V, et al. Reliability of bladder
volume measurement with BladderScan in paediatric patients. Scand J
Urol Nephrol. 2006;40(5):370-375.
Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and
validation of patient-reported outcomes measures for overactive bladder:
a review of concepts. Urology. Aug 2006;68(2 Suppl):9-16.
Chartier-Kastler E, Tubaro A. The Measurement of Nocturia and Its
Impact on Quality of Sleep and Quality of Life in LUTS/BPH. European
Urology Supplements. 2006;5(1):9.
Chapple CR, Batista JE, Berges R, et al. The Impact of Nocturia in Patients
with LUTS/BPH: Need for New Recommendations. European Urology
Supplements. 2006;5(1):7.
Artibani W, Pesce F, Prezioso D, et al. Italian validation of the urogenital
distress inventory and its application in LUTS patients. Eur Urol. Dec
2006;50(6):1323-1329.
Acquadro C, Kopp Z, Coyne KS, et al. Translating overactive bladder
questionnaires in 14 languages. Urology. Mar 2006;67(3):536-540.
Tubaro A, Palleschi G. Overactive bladder: epidemiology and social
impact. Curr Opin Obstet Gynecol. Oct 2005;17(5):507-511.
Tubaro A, De Nunzio C, Trucchi A, Palleschi G, Miano L. The effect of
bladder outlet obstruction treatment on ultrasound-determined bladder
wall thickness. Rev Urol. 2005;7 Suppl 6:S35-42.
Trucchi A, De Nunzio C, Mariani S, Palleschi G, Miano L, Tubaro A. Local
anesthesia reduces pain associated with transrectal prostatic biopsy. A
prospective randomized study. Urol Int. 2005;74(3):209-213.
Speakman M, Batista J, Berges R, et al. Integrating risk profiles for disease
progression in the treatment choice for patients with lower urinary tract
symptoms/benign prostatic hyperplasia: a combined analysis of external
evidence and clinical expertise. Prostate Cancer Prostatic Dis.
2005;8(4):369-374.
Palleschi G, Tubaro A, Miano L. [Overactive bladder: modulating the
effects of antimuscarinic therapy]. Minerva Urol Nefrol. Dec
2005;57(4):237-245.
Ockrim J, Laniado ME, Khoubehi B, et al. Variability of detrusor
overactivity on repeated filling cystometry in men with urge symptoms:
comparison with spinal cord injury patients. BJU Int. Mar
2005;95(4):587-590.
Lowe FC, Batista J, Berges R, et al. Risk factors for disease progression in
patients with lower urinary tract symptoms/benign prostatic hyperplasia
(LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer
Prostatic Dis. 2005;8(3):206-209.
De Nunzio C, Franco G, Leonardo C, Trucchi A, Tubaro A, Laurenti C. Effect
of once-daily alfuzosin on urinary symptoms and flow rate in benign
prostatic hyperplasia : a 24-hour home-uroflowmetry evaluation. Clin
Drug Investig. 2005;25(6):359-365.
Bellorofonte C, Vedruccio C, Tombolini P, Ruoppolo M, Tubaro A. Noninvasive detection of prostate cancer by electromagnetic interaction. Eur
Urol. Jan 2005;47(1):29-37; discussion 37.
Vicentini C, Gravina GL, Angelucci A, et al. Detection of telomerase activity
in prostate massage samples improves differentiating prostate cancer
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
Pagina 9 - Curriculum vitae di
[ TUBARO Andrea ]
from benign prostatic hyperplasia. J Cancer Res Clin Oncol. Apr
2004;130(4):217-221.
Tubaro A, La Vecchia C. The relation of lower urinary tract symptoms
with life-style factors and objective measures of benign prostatic
enlargement and obstruction: an Italian survey. Eur Urol. Jun
2004;45(6):767-772.
Tubaro A, De Nunzio C. Re: See W, Iversen P, Wirth M, McLeod D, Garside
L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant
therapy significantly reduces the risk of PSA progression in early
prostatic cancer. Eur Urol 2003;44:512-8. Eur Urol. May 2004;45(5):674;
author reply 674-675.
Tubaro A. Defining overactive bladder: epidemiology and burden of
disease. Urology. Dec 2004;64(6 Suppl 1):2-6.
Laniado ME, Ockrim JL, Marronaro A, Tubaro A, Carter SS. Serum
prostate-specific antigen to predict the presence of bladder outlet
obstruction in men with urinary symptoms. BJU Int. Dec
2004;94(9):1283-1286.
Carbone A, Palleschi G, Ciavarella S, et al. Experience with a bone anchor
sling for treating female stress urinary incontinence: outcome at 30
months. BJU Int. Apr 2004;93(6):780-788.
Tubaro A, Trucchi A, Miano L. Investigation of benign prostatic
hyperplasia. Curr Opin Urol. Jan 2003;13(1):17-22.
Tubaro A, Carter S, Trucchi A, Punzo G, Petta S, Miano L. Early treatment
of benign prostatic hyperplasia: implications for reducing the risk of
permanent bladder damage. Drugs Aging. 2003;20(3):185-195.
Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic
hyperplasia: a progressive disease of aging men. Urology. Feb
2003;61(2):267-273.
Vicentini C, Festuccia C, Angelucci A, et al. Bicalutamide dose-dependently
inhibits proliferation in human prostatic carcinoma cell lines and primary
cultures. Anticancer Res. Sep-Oct 2002;22(5):2917-2922.
Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence
of lower urinary tract symptoms suggestive of benign prostatic
hyperplasia in primary care--the Triumph project. Eur Urol. Oct
2002;42(4):323-328.
Tubaro A, Polito M, Giambroni L, Famulari C, Gange E, Ostardo E. Sexual
function in patients with LUTS suggestive of BPH. European Urology
Supplements. 2001;40 Suppl 1:19-22.
Tubaro A, Carter S, Hind A, Vicentini C, Miano L. A prospective study of
the safety and efficacy of suprapubic transvesical prostatectomy in
patients with benign prostatic hyperplasia. The Journal of urology. Jul
2001;166(1):172-176.
Ockrim JL, Laniado ME, Patel A, Tubaro A, St Clair Carter S. A probability
based system for combining simple office parameters as a predictor of
bladder outflow obstruction. J Urol. Dec 2001;166(6):2221-2225.
Tubaro A, Vicentini C, Renzetti R, Miano L. Invasive and minimally
invasive treatment modalities for lower urinary tract symptoms: what
are the relevant differences in randomised controlled trials? European
Urology Supplements. 2000;38 Suppl 1:7-17.
Tubaro A, Miano L. Managing the Consequences of Obstruction. European
Urology Supplements. 2000;1:7.
Carter S, Tubaro A. Relation between intraprostatic temperature and
clinical outcome in microwave thermotherapy. J Endourol. Oct
2000;14(8):617-625.
Tubaro A, Montanari E. Management of symptomatic BPH in Italy: who is
treated and how? Eur Urol. 1999;36 Suppl 3:28-32.
Tubaro A. The use of voiding studies (flowmetry and urodynamics) in the
assessment and follow-up of patients. Curr Opin Urol. Jan 1999;9(1):1520.
Scattoni V, Raber M, Montorsi F, et al. Percent of free serum prostatespecific antigen and histological findings in patients undergoing open
prostatectomy for benign prostatic hyperplasia. European urology. Dec
1999;36(6):621-630.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
Pagina 10 - Curriculum vitae di
[ TUBARO Andrea ]
Tubaro A, d'Ancona FC. Case selection for high-energy transurethral
microwave thermotherapy. World J Urol. 1998;16(2):124-130.
Russo F, Marinaro A, Sebastiani G, et al. [The Studer orthotopic ileal
neobladder: patient compliance]. Arch Ital Urol Androl. Jun 1998;70(3
Suppl):47-53.
Russo F, Di Pasquale B, Romano G, et al. [International prostate symptom
score: comparison of doctor and patient]. Arch Ital Urol Androl. Jun
1998;70(3 Suppl):15-24.
Manieri C, Carter SS, Romano G, Trucchi A, Valenti M, Tubaro A. The
diagnosis of bladder outlet obstruction in men by ultrasound
measurement of bladder wall thickness. J Urol. Mar 1998;159(3):761765.
Hofner K, Tubaro A, de la Rosette JJ, Carter SS. Analysis of outcome after
thermotherapy using different classifications of bladder outlet
obstruction. Neurourol Urodyn. 1998;17(2):109-120.
Trucchi A, Franco G, Manieri C, Valenti M, Carter SS, Tubaro A. Manual
versus computer methods for diagnosing obstruction from pressure-flow
tracings in patients with benign prostatic hyperplasia. J Urol. Mar
1997;157(3):871-875.
de la Rosette JJ, de Wildt MJ, Hofner K, Carter SS, Debruyne FM, Tubaro A.
High energy thermotherapy in the treatment of benign prostatic
hyperplasia: results of the European Benign Prostatic Hyperplasia Study
Group. J Urol. Jul 1996;156(1):97-101; discussion 101-102.
de la Rosette JJ, de Wildt MJ, Hofner K, Carter SS, Debruyne FM, Tubaro A.
Pressure-flow study analyses in patients treated with high energy
thermotherapy. J Urol. Oct 1996;156(4):1428-1433.
Tubaro A, Stoppacciaro A, Velotti F, et al. Local immunotherapy of
superficial bladder cancer by intravesical instillation of recombinant
interleukin-2. Eur Urol. 1995;28(4):297-303.
Tubaro A, Carter SSC, de la Rosette J, Hofner K, Miano L. Transurethral
microwave heating, current status and future perspectives. J Urol (Paris).
1995;101(1):29-32.
Tubaro A, Carter SS, de la Rosette J, et al. The prediction of clinical
outcome from transurethral microwave thermotherapy by pressure-flow
analysis: a European multicenter study. J Urol. May 1995;153(5):15261530.
de Wildt MJ, Tubaro A, Hofner K, Carter SS, de la Rosette JJ, Devonec M.
Responders and nonresponders to transurethral microwave
thermotherapy: a multicenter retrospective analysis. J Urol. Nov
1995;154(5):1775-1778.
de la Rosette JJ, Tubaro A, Trucchi A, Carter SS, Hofner K. Changes in
pressure-flow parameters in patients treated with transurethral
microwave thermotherapy. J Urol. Oct 1995;154(4):1382-1385.
de la Rosette JJ, Tubaro A, Hofner K, Carter SS. Transurethral microwave
thermotherapy: past, present and future. World J Urol. 1994;12(6):352356.
Tubaro A, Paradiso Galatioto G, Trucchi A, Miano L. [Transurethral
thermotherapy by microwaves in patients with benign obstructive
prostatic hypertrophy]. J Urol (Paris). 1993;99(6):338-343.
Tubaro A, Paradiso Galatioto G, Trucchi A, et al. Transurethral microwave
thermotherapy in the treatment of symptomatic benign prostatic
hyperplasia. Eur Urol. 1993;23(2):285-291.
Bologna M, Vicentini C, Corrao G, et al. Early diagnosis of prostatic
carcinoma may be achieved through in vitro culture of tumor cells
harvested by prostatic massage. Eur Urol. 1993;24(1):148-155.
Velotti F, Giuffrida A, Cippitelli M, et al. Soluble and cell-associated IL-2
receptor (IL-2R) after local immunotherapy with recombinant
interleukin-2 (rIL-2). Pharmacol. Res. 1992;26(Suppl. 2):2.
Velotti F, Stoppacciaro A, Ruco L, et al. Local activation of immune
response in bladder cancer patients treated with intraarterial infusion of
recombinant interleukin-2. Cancer Res. May 1 1991;51(9):2456-2462.
Tubaro A, Velotti F, Stoppacciaro A, et al. Continuous intra-arterial
administration of recombinant interleukin-2 in low-stage bladder cancer.
143.
144.
145.
146.
147.
148.
149.
LIBRI
CAPITOLI DI LIBRI
Pagina 11 - Curriculum vitae di
[ TUBARO Andrea ]
A phase IB study. Cancer. Jul 1 1991;68(1):56-61.
Miano L, Vicentini C, Manieri C, Tubaro A, Galatioto GP. The Studer-Zingg
ileal-neobladder: the "ideal" bladder substitute? Prog Clin Biol Res.
1991;370:67-68.
Velotti F, Tubaro A, Stoppacciaro A, et al. Local/regional recombinant
interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous
infusion of rIL-2 in bladder cancer patients: a phase I study. Ann Ist Super
Sanita. 1990;26(3-4):411-421.
Miano L, Goldoni S, Tubaro A, Paradiso Galatioto G, Gandolfi P. Review of
norfloxacin in lower urinary tract infections. European Urology
Supplements. 1990;17 Suppl 1:13-18.
Beomonte Zobel B, Vicentini C, Masciocchi C, et al. Magnetic resonance
imaging in the localization of undescended abdominal testes. Eur Urol.
1990;17(2):145-148.
Goldoni S, Gandolfi P, Tubaro A, Vicentini C, Lancione P, Miano L.
Evaluation of the efficacy and safety of imipenem/cilastatin in the
treatment of complicated urinary tract infections. J Chemother. Jul
1989;1(4 Suppl):845-847.
Petta S, Tubaro A. [Clinico-diagnostic approach to the patient with
erection disorders]. Clin Ter. Jul 31 1984;110(2):169-171.
Perugia G, Petta S, Tubaro A, et al. [Transrectal prostatic cytology using
needle aspiration. Review of 832 cases]. Minerva Urol Nefrol. Jan-Mar
1984;36(1):5-8.
1)
Current Therapy of Benign Prostatic Hyperplasia. C. Chapple and A. Tubaro. Eds. Martin
Dunitz Ltd., Londra, 2000;
2)
Urodinamica Clinica, Volume 1 - Tecnica. P. Di Benedetto, F. Pesce, Tubaro A. Eds.,
McGraw-Hill, Milano, 2003;
3)
Urodinamica Clinica, Volume 2 - Indicazioni. P. Di Benedetto, F. Pesce, Tubaro A. Eds.,
McGraw-Hill, Milano, 2005;
4)
Iperplasia Prostatica Benigna – Orientamento Diagnostico, Andrea Tubaro, Carocci
Editore, Roma, 2011
5)
Iperplasia Prostatica Benigna – Orientamento Terapeutico, Andrea Tubaro, Carocci
Editore, Roma, 2011
1)
A placebo-controlled double-blind study of allopurinol in severe recurrent idiopathic renal
lithiasis. Preliminary results. Miano L, Petta S, Paradiso Galatioto G, Goldoni S, Tubaro A.
In: Urolithiasis and Related Clinical Research. Schwille PO, Smith LH, Robertson WG,
Vahlensieck W. Eds. Plenum Publishing Corporation, pp: 521-524, 1985.
2)
Malattie dell’apparato urinario di interesse chirurgico. Miano L, Galassi P, Goldoni S,
Manieri C, Paradiso Galatioto G, Tubaro A, Vicentini C. In: Trattato Italiano di Medicina
Interna. P. Introzzi Ed., pp: 505.544, 1988.
3)
The Studer-Zingg ileal neobladder: the “ideal” bladder substitute? Miano L, Vicentini C,
Manieri C, Tubaro A, Paradiso Galatioto G, In: EORTC GU Group Monograph 10;
Reconstructive Surgery, Organ Conservation, and Funciton restoration in Urological
Oncology. PH Smith ed., New York, J Wiley and Sons, Inc. 1990.
4)
Local Immunotherapy on human bladder cancer with recombinant IL-2: activation of
immune response and possible direct effect action of IL-2 on tumour cells. Velotti F,
Cippitelli M. Giuffrida AM, Punturieri A, Moretti F. Stoppacciaro A, Tubaro A. De Maria R,
and Santoni A. In: Cytokine-induced tumour immunogenicity. Academic Press, 1994, pp:
429-442.
5)
“Analisi della ricerca urologica”, “Apparecchi di urodinamica: guida per una scelta oculata”,
“Apparecchiature ad alta tecnologia”, “Gli stent ureterali”, “L’urologo e l’aggiornamento”. A
Tubaro, In: L’Urologo Italiano, L. Miano, Ed., Hippocrates Ed., 1998, pp: 129-132; 161-171;
199-221.
6)
Open Prostatectomy. A. Tubaro, In: Current Therapy for Benign Prostatic Hyperplasia.
Martin Dunitz., Ltd. London 2000.
7)
The Urodynamics of LUTS. Abrams P, Griffiths D, Hoefner K, Nishizawa O, Schefer W,
Tubaro A, Zimmern PE, In: Benign Prostatic Hyperplasia. C. Chatelain, L. Denis, KT Foo,
S. Khoury, J. McConnell, Eds. Health Publications Ltd. Plymouth (UK), 2001: pp: 227-281.
8)
Imaging and Other Investigations: Artibani W, Anderson JT, Gajewski JB, Ostergard DR,
Raz S, Tubaro A, In: Incontinence, P. Abrams, L. Cardozo, S. Khoury, A. Wein, Eds. Health
Publication Ltd. Plymouth (UK), 2002, pp: 425-477.
9)
Imaging and Other Investigations. Tubaro A, Artibani W, Bartram C, Dietz HP, Khullar V,
DeLancey JD, Zimmern PE, In: Incontinence. P. Abrams, L. Cardozo, S. Khoury, A. Wein,
Eds. Health Publication Ltd. Plymouth (UK), 2005, pp: 707-797. ISBN 0-9546956-2-3.
10) Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia: what is the
evidence for rational diagnosis? A. Tubaro, C. De Nunzio, A. Trucchi. In: The Evidence for
Urology. Chris Dawson & Gordon Muir Eds. tfm Publishing Ltd., Shrewsbury (UK) 2005, pp:
89-96.
11) LUTS: Etiology and Patient Assessment. P. Abrams, C. D’Ancona, K.T. Foo, D. Griffiths, O.
Nishizawa, V. Nitti, A. Tubaro, P. van Kerrebroeck, A. Wein. In: Male Lower urinary Tract
Dysfunction. J. McConnell, P. Abrams, L. Denis. S. Khoury, C. Roehrborn, Eds. Health
Publications Ltd. 2006, ISBN 0-9546956-6-6, pp: 69-142.
12) Radiological Imaging. Tubaro A, Carbone A, Trucchi A. in: Textbook of female Urology and
Urogynecology. Linda Cardozo and David Staskin Eds. Informa Healthcare, 2006, Oxon
(UK), pp 339-353.
13) Imaging, Neurophysiology and Other Investigations. A. Tubaro, G. Amarenco, W. Artibani,
C. Bartram, M. De Gennaro. J. De Lancey, V. Khullar, K. Kluivers, S. Podnar, M. Vierhout,
D. Vodusek. In: Incontinence, Paul Abrams, Linda Cardozo, Alan Wien, Eds., Health
Publication Ltd, 2009, pp: 485 - 517.
14) Bladder Ultrasound in Voiding Dysfunction. A Tubaro and M. De Gennaro. In: Atlas of
Bladder Disease. D. Stakin Ed. Springer, Philadelphia, 2010, pp: 81-96.
15) Imaging of the Lower Urinary Tract (radiology and ultrasound). Tubaro A, Carbone A,
Trucchi A. in: Textbook of female Urology and Urogynecology. Third Edition. Linda Cardozo
and David Staskin Eds. Informa Healthcare, 2010, Oxon (UK), Chapter 36.
Prof. Andrea Tubaro
Roma, 30 novembre 2012
Pagina 12 - Curriculum vitae di
[ TUBARO Andrea ]

Documenti analoghi